NASDAQ:IGMS IGM Biosciences (IGMS) Stock Forecast, Price & News $7.28 -0.18 (-2.41%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$6.95▼$7.5050-Day Range$6.66▼$10.6452-Week Range$6.45▼$28.20Volume287,574 shsAverage Volume228,525 shsMarket Capitalization$424.93 millionP/E RatioN/ADividend YieldN/APrice Target$23.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability IGM Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside224.2% Upside$23.60 Price TargetShort InterestBearish28.16% of Float Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews Sentiment0.21Based on 2 Articles This WeekInsider TradingAcquiring Shares$931,850 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($5.16) to ($4.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.51 out of 5 starsMedical Sector159th out of 963 stocksPharmaceutical Preparations Industry57th out of 458 stocks 4.3 Analyst's Opinion Consensus RatingIGM Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.60, IGM Biosciences has a forecasted upside of 224.2% from its current price of $7.28.Amount of Analyst CoverageIGM Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted28.16% of the float of IGM Biosciences has been sold short.Short Interest Ratio / Days to CoverIGM Biosciences has a short interest ratio ("days to cover") of 19, which indicates bearish sentiment.Change versus previous monthShort interest in IGM Biosciences has recently increased by 2.92%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIGM Biosciences does not currently pay a dividend.Dividend GrowthIGM Biosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIGM Biosciences has received a 71.95% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Clinical research services for infectious diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for IGM Biosciences is -1.08. Previous Next 2.3 News and Social Media Coverage News SentimentIGM Biosciences has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for IGM Biosciences this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for IGMS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IGM Biosciences insiders have bought 10,468.79% more of their company's stock than they have sold. Specifically, they have bought $931,850.00 in company stock and sold $8,817.00 in company stock.Percentage Held by Insiders56.91% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.21% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IGM Biosciences are expected to grow in the coming year, from ($5.16) to ($4.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGM Biosciences is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGM Biosciences is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGM Biosciences has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IGM Biosciences (NASDAQ:IGMS) StockIGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Read More IGMS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGMS Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comOrchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?September 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CVS Health (CVS), IGM Biosciences (IGMS) and Adverum Biotechnologies (ADVM)September 24, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 7, 2023 | msn.comTruist Securities Reiterates IGM Biosciences (IGMS) Buy RecommendationSeptember 6, 2023 | finance.yahoo.comIGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 17, 2023 | msn.comRBC Capital Reiterates IGM Biosciences (IGMS) Sector Perform RecommendationAugust 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Intuitive Surgical (ISRG)August 11, 2023 | finance.yahoo.comDown More Than 50%: These 2 ‘Strong Buy’ Stocks Are Too Cheap to IgnoreSeptember 24, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 8, 2023 | msn.comMorgan Stanley Maintains IGM Biosciences (IGMS) Equal-Weight RecommendationAugust 8, 2023 | msn.comNeedham Downgrades IGM Biosciences (IGMS)August 4, 2023 | finanznachrichten.deIGM Biosciences, Inc.: IGM Biosciences Announces Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comIGM Biosciences Announces Second Quarter 2023 Financial ResultsJuly 3, 2023 | finance.yahoo.comIGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional SharesJune 30, 2023 | finance.yahoo.comWhile hedge funds own 27% of IGM Biosciences, Inc. (NASDAQ:IGMS), individual investors are its largest shareholders with 28% ownershipJune 23, 2023 | finance.yahoo.comStrength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?June 22, 2023 | markets.businessinsider.comWhy IGM Biosciences (IGMS) Stock Is Trading HigherJune 22, 2023 | finance.yahoo.comIGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private PlacementJune 21, 2023 | msn.comIGM Biosciences plans for $100M stock offering and concurrent private placementJune 21, 2023 | finance.yahoo.comIGM Announces Proposed Public Offering and Concurrent Private PlacementJune 7, 2023 | markets.businessinsider.comRobert W. Baird Sticks to Its Buy Rating for IGM Biosciences (IGMS)June 6, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Legend Biotech (LEGN), Shattuck Labs (STTK)June 6, 2023 | msn.comHC Wainwright & Co. Reiterates IGM Biosciences (IGMS) Buy RecommendationJune 5, 2023 | msn.comWedbush Reiterates IGM Biosciences (IGMS) Outperform RecommendationJune 1, 2023 | finance.yahoo.comIGM Biosciences to Present at the Jefferies Healthcare ConferenceMay 31, 2023 | finance.yahoo.comIGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid ArthritisMay 30, 2023 | finance.yahoo.comIGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical UpdateSee More Headlines Receive IGMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address IGMS Company Calendar Last Earnings8/03/2023Today9/24/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IGMS CUSIPN/A CIK1496323 Webigmbio.com Phone650-965-7873FaxN/AEmployees289Year Founded2010Price Target and Rating Average Stock Price Forecast$23.60 High Stock Price Forecast$55.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+224.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($5.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-221,100,000.00 Net Margins-14,007.47% Pretax Margin-13,995.76% Return on Equity-84.18% Return on Assets-46.92% Debt Debt-to-Equity RatioN/A Current Ratio9.07 Quick Ratio9.07 Sales & Book Value Annual Sales$1.07 million Price / Sales397.13 Cash FlowN/A Price / Cash FlowN/A Book Value$6.67 per share Price / Book1.09Miscellaneous Outstanding Shares58,370,000Free Float25,150,000Market Cap$424.93 million OptionableNot Optionable Beta-0.24 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Fred M. Schwarzer J.D. (Age 70)CEO, Pres & Director Comp: $977.66kDr. Bruce A. Keyt (Age 70)Chief Scientific Officer Comp: $692.95kDr. Chris H. Takimoto FACP (Age 64)M.D., Ph.D., Chief Medical Officer Comp: $684.95kMr. Misbah Tahir (Age 48)Chief Financial Officer Mr. TS HarigopalSr. VP of Group OperationsMr. Steven Weber (Age 47)Sr. VP, Corp. Controller & Principal Accounting Officer Mr. Paul C. GraffagninoVP of Legal AffairsMs. Suzette Tauber (Age 59)Chief HR Officer Dr. Angus M. Sinclair Ph.D.Sr. VP of Immuno-OncologyDr. Lisa L. Decker Ph.D. (Age 54)Chief Bus. Officer More ExecutivesKey CompetitorsLiquidiaNASDAQ:LQDAProcaps GroupNASDAQ:PROCArcutis BiotherapeuticsNASDAQ:ARQTJanux TherapeuticsNASDAQ:JANXMineralys TherapeuticsNASDAQ:MLYSView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 2,674 shares on 8/21/2023Ownership: 0.027%Nuveen Asset Management LLCSold 1,982 shares on 8/16/2023Ownership: 0.136%Wells Fargo & Company MNBought 2,529 shares on 8/15/2023Ownership: 0.008%Lazard Asset Management LLCBought 2,894 shares on 8/15/2023Ownership: 0.005%Citadel Advisors LLCSold 4,100 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions IGMS Stock - Frequently Asked Questions Should I buy or sell IGM Biosciences stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IGMS shares. View IGMS analyst ratings or view top-rated stocks. What is IGM Biosciences' stock price forecast for 2023? 8 brokerages have issued 1-year price objectives for IGM Biosciences' shares. Their IGMS share price forecasts range from $11.00 to $55.00. On average, they anticipate the company's stock price to reach $23.60 in the next twelve months. This suggests a possible upside of 224.2% from the stock's current price. View analysts price targets for IGMS or view top-rated stocks among Wall Street analysts. How have IGMS shares performed in 2023? IGM Biosciences' stock was trading at $17.01 at the beginning of the year. Since then, IGMS stock has decreased by 57.2% and is now trading at $7.28. View the best growth stocks for 2023 here. When is IGM Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our IGMS earnings forecast. How were IGM Biosciences' earnings last quarter? IGM Biosciences, Inc. (NASDAQ:IGMS) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.40) by $0.03. The business earned $0.45 million during the quarter, compared to analysts' expectations of $0.80 million. IGM Biosciences had a negative trailing twelve-month return on equity of 84.18% and a negative net margin of 14,007.47%. The company's revenue for the quarter was up 22.4% on a year-over-year basis. During the same period in the previous year, the business earned ($1.33) EPS. What ETFs hold IGM Biosciences' stock? ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of IGM Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET). When did IGM Biosciences IPO? (IGMS) raised $125 million in an IPO on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO. What is IGM Biosciences' stock symbol? IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS." Who are IGM Biosciences' major shareholders? IGM Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Artal Group S.A. (5.85%), RA Capital Management L.P. (1.61%), BlackRock Inc. (1.99%), Goldman Sachs Group Inc. (1.15%), Great Point Partners LLC (0.86%) and State Street Corp (0.45%). Insiders that own company stock include Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg and Misbah Tahir. View institutional ownership trends. How do I buy shares of IGM Biosciences? Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IGM Biosciences' stock price today? One share of IGMS stock can currently be purchased for approximately $7.28. How much money does IGM Biosciences make? IGM Biosciences (NASDAQ:IGMS) has a market capitalization of $424.93 million and generates $1.07 million in revenue each year. The company earns $-221,100,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis. How many employees does IGM Biosciences have? The company employs 289 workers across the globe. How can I contact IGM Biosciences? IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is igmbio.com. The company can be reached via phone at 650-965-7873. This page (NASDAQ:IGMS) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.